IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with rare kidney disease: drug trial launches
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see how the drug works in the body, if it is safe, and if it can reduce protein in the urine, a sign of kidney damage. About 24 children will take part…
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New hope for kidney disease: ravulizumab trial targets protein leak
Disease control Recruiting nowThis phase 3 study tests whether ravulizumab can reduce protein in urine and slow kidney function decline in adults with IgA nephropathy, a disease that can lead to kidney failure. About 510 participants will receive either the drug or a placebo. The goal is to see if the drug he…
Matched conditions: IGAN
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New hope for kidney patients: drug targets autoimmune attack
Disease control Recruiting nowThis study tests a drug called atacicept in 200 adults and teens with autoimmune kidney diseases like IgA nephropathy and FSGS. The goal is to see if it safely reduces protein in the urine and helps protect kidney function. Participants must already be on standard treatment.
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC